Editorial · 27 Jan 2021
Conference abstractPublished 25 Sep 2014
Current restructuring ordeal & the future ahead for CMOs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
With the sunset of the blockbuster era and increasing demand for more low-costs generics are expected to change the dynamics of CMO and API business in the near future. In the last 3 decades, outsourcings across CMO operations have increases from 10% to 25%. Demand Trends: With the availability of quality outsourcing partners and underutilized capacity with the large pharma sponsors has made the large pharma to rethink their procurement and manufacturing strategy. Pharma sponsors are expected to increase their dependencies on potential strategic suppliers, to make their in-house manufacturing operation more lean and efficient. In response, Industry is also witnessing many asset rationalization deals in the past few years, to mitigate the underutilization rate for CMO and API manufacturing operations. Supply Trends: Recent evolution and reforms in the regulatory front, is mainly focused towards monitoring the quality and operations of Emerging Market CMOs/Suppliers like in India and China. In order to mitigate these challenges CMOs with country of origin form Emerging markets like India and China are expanding their operations to developed markets like US and EU to ensure quality and innovation. These in turn is making Procurement the Game Changer to increase future productivity, quality and derive cost efficiencies for Pharma Manufacturing Operations by outsourcing to potential CMOs. Objective: The research paper will mainly discuss the impact of these trends on Buyers (Pharmaceutical) and Suppliers (CMOs) and highlight key focus areas and future course from procurement prospective ? Supplier Base consolidation by adopting tail-end spend management ? Increasing manufacturing operational footprint in LCCs ? Establishing and optimizing Pharma- CRO Strategic Deals
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · Jun 2014
Molecular pharming in plants and plant cell cultures: a great future ahead?
Article · 7 Jul 2025
Biopharmaceutical Characterization of Oral Insulin Formulations: Current Status and Future Prospects
Editorial · 28 Feb 2025
Pharmacological Implications of Neurodegenerative Diseases: Current and Future Therapies
Opinion · 28 Feb 2025
Pharmacological Strategies for Managing Chronic Diseases: Current Trends and Future Directions
More from this journal
The newest in Journal of Developing Drugs.
Research article · 17 Jul 2026
Effects of a Food-Derived GLP-1 Formula on Endogenous GLP-1 Secretion and Appetite Responses: A Randomized Double-Blind Crossover Study
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kamaljit Behera”

